All In Biotech

Free tool

FAERS Monitor: Amjevita

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761024 or its brand name (Amjevita, Adalimumab-Atto). Reports on generic versions are filed under their own applications.

Reports

1,610

Serious

423

26% of reports

Hospitalization

152

Death reported

19

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • device difficult to use379
  • product storage error280
  • drug dose omission by device247
  • circumstance or information capable of leading to medication error194
  • accidental exposure to product164
  • injection site pain125
  • drug ineffective90
  • wrong technique in product usage process87
  • intercepted product administration error75
  • pain71
  • off label use68
  • product communication issue68
  • rheumatoid arthritis51
  • arthralgia40
  • device use error38

Reports by year received

View as table
YearReports
20171
20185
20196
202015
202113
20225
2023493
2024433
2025305
2026334

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,549 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intercepted product administration errorSignal75129.0103.39,313
product communication issueSignal68101.580.36,616
circumstance or information capable of leading to medication errorSignal19475.566.114,121
device difficult to useSignal37975.268.927,613
product storage errorSignal28041.937.711,153
drug dose omission by deviceSignal24741.336.89,687
accidental exposure to productSignal16420.818.03,085
device use errorSignal3814.310.4457
rheumatoid arthritisSignal515.94.5202
wrong technique in product usage processSignal875.64.6328
injection site painSignal1255.34.5441
pain711.51.212
arthralgia401.30.92
off label use681.00.80
drug ineffective900.90.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.